Canopy Growth Corporation CGC

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
35/100
Developing

About Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including … Full CGC analysis →

Competitive advantage assessment

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.69), providing operational cushion.
  • Operating Leverage in Effect Operating leverage is evident (score 0.89), with margins expanding over time.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 20.0th percentile with high volatility suggests weak pricing power or commoditized products.
  • Below-Peer Operating Efficiency Operating margin at 23.8th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
13

Where CGC ranks in Drug Manufacturers - Specialty & Generic

Canopy Growth Corporation ranks #59 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 65%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near CGC in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
55 Biofrontera Inc. Warrants BFRIW 37/100 Developing
56 IM Cannabis Corp. IMCC 37/100 Developing
57 Alpha Teknova, Inc. TKNO 36/100 Developing
58 Universe Pharmaceuticals Inc UPC 36/100 Developing
59 Canopy Growth Corporation CGC 35/100 Developing
60 SCYNEXIS, Inc. SCYX 34/100 Developing
61 Cardiol Therapeutics Inc. CRDL 33/100 Developing
62 Zhengye Biotechnology Holding L ZYBT 32/100 Developing
63 Assertio Holdings, Inc. ASRT 32/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How CGC scores on the Corporate Default defenses

Pricing Power

Score 13 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 38 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 44 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 26 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 48 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 49 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CGC's moat

What is Canopy Growth Corporation's moat score?

Canopy Growth Corporation (CGC) scores 35 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #59 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 65%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (49/100) and its weakest is Pricing Power (13/100).

How does Canopy Growth Corporation compare with other Drug Manufacturers - Specialty & Generic companies?

Canopy Growth Corporation ranks #59 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Universe Pharmaceuticals Inc (UPC) at 36 just above it and SCYNEXIS, Inc. (SCYX) at 34 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Canopy Growth Corporation scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Canopy Growth Corporation?

The Corporate Default template measures 6 defenses, and CGC scores: Pricing Power (13), Cost Advantage (38), Customer Stickiness (44), Capital Efficiency (26), Resilience (48), Scale & Market Position (49). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000